Volume 25, Number 6—June 2019
Research Letter
Absence of Neospora caninum DNA in Human Clinical Samples, Spain
Table
Native country | |
---|---|
Spain | 382 (63.7) |
Other† | 36 (6.0) |
Unknown |
182 (30.3) |
Patient clinical information | |
Immune status | |
Immunocompetent | 458 (76.3) |
Immunodepressed or immunosuppressed | 83 (13.8) |
HIV/AIDS | 19 (22.9) |
Chemotherapy | 29 (34.9) |
Organ transplant | 35 (42.2) |
Unknown | 59 (9.8) |
Pregnancy-related disorders | 454 (75.7) |
Seroconversion–infection suspicion and lymphadenopathy | 418 (92.1) |
Spontaneous abortion | 27 (5.9) |
Ophthalmic | 4 (0.9) |
Other fetal signs‡ | 5 (1.1) |
Neurologic and ocular symptoms and conditions§ | 108 (18.0) |
Neurologic condition with ocular signs | 8 (7.4) |
Ophthalmic only | 3 (2.7) |
General signs, n = 38 | 38 (6.3) |
Pneumonia | 24 (63.2) |
Lymphadenopathy | 2 (5.3) |
Hematologic or oncologic | 12 (31.6) |
*Patients were from 12 regions: Andalusia, Aragon, Asturias, Balearic Islands, Cantabria, Castile-La Mancha, Castile and Leon, Extremadura, Galicia, Madrid, Navarre, Valencia.
†Africa, 8; Asia, 1; Europe, 8; Latin America, 19.
‡Anencephaly, malformations, and microcephaly.
§Neurologic symptoms and conditions include ataxia, disorientation, sudden blindness, encephalitis, calcifications, and intracranial space occupying lesions; ophthalmic symptoms and conditions include chorioretinitis, panuveitis, posterior uveitis, and vitritis.
Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.